Bringing the fundamentals into focus…
Back to Ultragenyx Pharmaceutical Inc.
How Ultragenyx Pharmaceutical Inc. stacks up
RARE · against 404 other Healthcare companies of similar size
Growth
63/ 100
Above the middle of the pack.
Ranked #157 of 405 · scores higher than 60% of peers
Bars: peers in each 10-point band of the growth score50 peers with a growth score of 60–69, including RARE · Click a bar to see the companies
Why growth scores 63?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its 3-year revenue growth and revenue growth, which are stronger than most Healthcare peers.
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
- faster revenue growth over the last year: stronger than 76% of peers. Revenue growth: 17.5% vs peer median 6.1%
- faster revenue growth over three years: stronger than 81% of peers. 3-year revenue growth: 21.2% vs peer median 5.8%
Metric by metric
Position: dot = RARE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RARE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 408 reported | 17.5% | 6.2% | 75% | 33% | |
| Earnings per share growthHigher is better · 223 reported | Not reported | 9.8% | — | — | 33% |
| 3-year revenue growthHigher is better · 396 reported | 21.2% | 6.9% | 78% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around RARE| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 1 | 1.4B USD | 99 | 73 | |
| 1 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 1 | 2.1B USD | 99 | 96 | |
| 1 | 2.8B USD | 99 | 51 | |
| 157 | 10.8B SAR (≈$2.9B) | 63 | 68 | |
| 157 | 10.8B CNY (≈$1.5B) | 63 | 80 | |
| 157 | 866M EUR (≈$952M) | 63 | 65 | |
| 157 | 11.1B BRL (≈$2.0B) | 63 | 60 | |
| 157 | 1.6B USD | 63 | 24 | |
| 163 | 8.2B CNY (≈$1.2B) | 62 | 50 | |
| 163 | 2.05T KRW (≈$1.5B) | 62 | 81 | |
| 163 | 1.5B USD | 62 | 26 | |
| 163 | 40.2B MXN (≈$2.2B) | 62 | 71 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score